Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1827 - Tepotinib plus gefitinib in patients with c-Met-positive/EGFR-mutant NSCLC: Recommended phase II dose (RP2D), tolerability, and efficacy


08 Oct 2016


Poster Display


Yi-Long Wu


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


Y. Wu1, R. Soo2, D. Kim3, J. Yang4, U. Stammberger5, W. Chen6, G. Locatelli5, K. Park7

Author affiliations

  • 1 Guangdong Lung Cancer Institute, Guangdong General Hospital, 510080 - Guangzhou/CN
  • 2 Cancer Institute, National University Cancer Institute, Singapore, Singapore/SG
  • 3 Department Of Internal Medicine, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
  • 4 Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW
  • 5 Global Clinical Development, Global Research And Development, Merck KGaA, 64293 - Darmstadt/DE
  • 6 Merck, Merck KGaA, Beijing/CN
  • 7 Div Of Hem/onc, Dept Of Med, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR


Abstract 1827


Patients (pts) with NSCLC treated with EGFR inhibitors (EGFRi) ultimately develop resistance, often through c-Met activation. Dual EGFR and c-Met inhibition is therefore a rational option to treat c-Met + , EGFRi-resistant NSCLC. Tepotinib is a highly selective c-Met inhibitor with good tolerability and promising efficacy against solid tumors. This phase Ib trial, conducted in Asia, examined tepotinib plus gefitinib in pts with c-Met + /EGFR-mutant NSCLC.


Pts aged ≥18 years were eligible if they had locally advanced/metastatic NSCLC, ECOG PS 0–1, EGFR mutation confirmed by Therascreen EGFR RGQ PCR (Qiagen), and c-Met positivity determined by IHC using CONFIRM anti-c-Met mAb (SP44; Ventana/Roche). A 3 + 3 design was used with expansion at the RP2D. Pts received tepotinib 300 or 500 mg/day plus gefitinib 250 mg/day (T300G250 or T500G250). The primary objective was to determine the RP2D of tepotinib plus gefitinib; secondary objectives included pharmacokinetics (PK), safety, and antitumor activity.


18 pts were enrolled (median age 65 [41–78], male 8). Pts had received a median of 2 (1–8) prior regimens including an EGFRi. 6 received T300G250, 12 T500G250. No dose-limiting toxicities were observed, and tepotinib 500 mg/day was confirmed as the RP2D. T500G250 was associated with treatment-related grade ≥3 increased amylase (n = 2), increased lipase (2), neutropenia (1) and hyperglycemia (1). No evidence of cumulative toxicity was noted. The best overall response was partial response in 5/18 pts, 4 with IHC 3+ tumors treated with T500G250 and 1 with an IHC 2+ tumor (T300G250). 4/18 pts had stable disease (SD) (3 IHC 2+ [1 T300G250, 2 T500G250], 1 IHC 3+ [T500G250]). PK were as expected based on historical comparisons.


Tepotinib was well tolerated in combination with gefitinib; the RP2D of tepotinib in combination with gefitinib in NSCLC is 500 mg/kg/day. Data show evidence of antitumor activity, with responses mainly in pts with c-Met IHC 3+ tumors and SD in pts with IHC 2+ tumors. A phase II trial is randomizing ∼136 pts with T790M–/c-Met+ tumors who have failed first-line gefitinib to tepotinib + gefitinib or cisplatin/pemetrexed.

Clinical trial identification


Legal entity responsible for the study

Global Clinical Development Center Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd


Merck KGaA


Y-L. Wu: Honoraria in the past two years from Roche, AstraZeneca, Eli Lilly, Sanofi. Research for Roche, AstraZeneca, Eli Lilly, Pfizer, Merck Serono, Novartis, BMS, ACEA Biosciences. R. Soo: Paid honoraria and consulted for AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche. Conducted research for AstraZeneca, Pfizer, Roche, Taiho, Merck-Serono, Novartis, Servier Bayer. J. Yang: Honoraria from AstraZeneca, Roche, Eli Lilly, Boehringer Ingelheim, Pfizer. Paid consultant to AstraZeneca, Roche/Genentech, Eli Lilly, Boehringer, Clovis, Novartis, Bayer, MSD, Merck, Pfizer, Astellas, Daichi-Sankyo, Celgene. Funder research Boehringer. U. Stammberger: Employee of Merck KGaA. W. Chen, G. Locatelli: Employee of Merck. K. Park: Advisory role for Astra Zeneca, Boehringer Ingeiheim, Clovis, Eli Lilly, Hanmi, ONO, Roche, in the past 2 years. Research for AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings